Please ensure Javascript is enabled for purposes of website accessibility

Why Clover Health Stock Fell in February

By Lou Whiteman - Mar 4, 2021 at 3:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A short-seller asks questions about the company's business.

What happened

Shares of Clover Health Investments (CLOV -1.44%) fell 32.6% in February, according to data provided by S&P Global Market Intelligence, after the company was targeted by short-seller Hindenburg Research. Hindenburg called Clover Health "a broken company" and provided a good enough argument to cause some investors to walk away from the stock.

So what

Clover became public through one of the special purpose acquisition companies (SPACs) backed by billionaire investor Chamath Palihapitiya. Clover is a medical insurance provider focused on Medicare Advantage plans that uses internally developed tech to try to improve patient outcomes, and their payments.

A doctor doing a virtual consultation.

Image source: Getty Images.

Palihapitiya called Clover "the greatest growth opportunity" that he's seen, but Hindenburg has its doubts. The firm in its report alleged Clover is under investigation by the U.S. Department of Justice, its sales are driven by misleading marketing practices, and that its signature tech product "deceives the healthcare system" and "poses a significant regulatory risk." 

Clover denied the allegations, but did confirm that there are some regulatory inquiries into its business.

Now what

It's hard to know what to make of any short report. Hindenburg has a decent track record, and there is a lot of meat contained in the report, but then again investigations are not uncommon and often turn out to be nothing.

Clover didn't help its cause in early March when it announced fourth-quarter results and provided 2021 guidance below expectations.

Clover is a relatively tiny Medicare insurer, with ample opportunities to grow its market share. But it is also operating in a highly regulated space where margins are limited, and it's relying on still-unproven tech to generate outsized returns. Investors need to watch this company closely, no matter what they think of the Hindenburg report.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Clover Health Investments, Corp. Stock Quote
Clover Health Investments, Corp.
CLOV
$2.74 (-1.44%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.